Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 1

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 1
---
 earlier effective registration statement for the same offering. ☐ If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐ If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. Emerging growth company ☒ If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ †The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. We hereby amend this Registration Statement on such date or dates as may be necessary to delay its effective date until we file a further amendment which will specifically state that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

EXPLANATORY NOTE This Post-Effective Amendment No. 1 to the Registration Statement on Form F-3 (Registration No. 333-287918) (the “Registration Statement”) of Connect Biopharma Holdings Limited is being filed to remove from registration all American Depositary Shares representing Ordinary Shares that were previously registered under such Registration Statement. Effective September 2, 2025, we terminated our American Depositary Receipt (“ADR”) program. At such time, our ADRs were mandatorily cancelled and exchanged for Ordinary Shares at a one-for-one ratio. On September 3, 2025, our Ordinary Shares commenced trading directly on the Nasdaq Global Market under the Company’s existing symbol “CNTB”. This registration statement contains:

| • |     | A base prospectus, which covers the offering, issuance and sales by us of up to $300,000,000 in the aggregate